HCAT vs. AMRN, ADCT, ANRO, OCGN, TRML, BVS, SLDB, MXCT, ANIK, and HROW
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Amarin (AMRN), ADC Therapeutics (ADCT), Alto Neuroscience (ANRO), Ocugen (OCGN), Tourmaline Bio (TRML), Bioventus (BVS), Solid Biosciences (SLDB), MaxCyte (MXCT), Anika Therapeutics (ANIK), and Harrow (HROW). These companies are all part of the "medical" sector.
Amarin (NASDAQ:AMRN) and Health Catalyst (NASDAQ:HCAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
Amarin has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
In the previous week, Health Catalyst had 7 more articles in the media than Amarin. MarketBeat recorded 13 mentions for Health Catalyst and 6 mentions for Amarin. Amarin's average media sentiment score of 0.45 beat Health Catalyst's score of 0.26 indicating that Health Catalyst is being referred to more favorably in the news media.
22.3% of Amarin shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 2.0% of Amarin shares are held by company insiders. Comparatively, 2.7% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Amarin currently has a consensus target price of $1.08, suggesting a potential upside of 25.24%. Health Catalyst has a consensus target price of $12.10, suggesting a potential upside of 89.36%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Health Catalyst is more favorable than Amarin.
Amarin received 697 more outperform votes than Health Catalyst when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 67.44% of users gave Health Catalyst an outperform vote.
Amarin has higher revenue and earnings than Health Catalyst. Amarin is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Amarin has a net margin of -18.96% compared to Amarin's net margin of -39.92%. Health Catalyst's return on equity of -9.48% beat Amarin's return on equity.
Summary
Amarin and Health Catalyst tied by winning 9 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
